Cargando…
Long-term outcomes of imatinib in patients with FIP1L1/PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China
BACKGROUND: The FIP1L1/PDGFRA (F/P) fusion gene is the most common clonal genetic abnormality of chronic eosinophilic leukemia (CEL). Tyrosine kinase inhibitors (TKI), such as imatinib, have been demonstrated to be effective therapies for F/P mutated disease. The aim of this study was to analyze the...
Autores principales: | Qu, Shi-Qiang, Qin, Tie-Jun, Xu, Ze-Feng, Zhang, Yue, Ai, Xiao-Fei, Li, Bing, Zhang, Hong-Li, Fang, Li-Wei, Pan, Li-Juan, Hu, Nai-Bo, Xiao, Zhi-Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078089/ https://www.ncbi.nlm.nih.gov/pubmed/27120808 http://dx.doi.org/10.18632/oncotarget.8906 |
Ejemplares similares
-
Chronic eosinophilic leukemia with FIP1L1-PDGFRA rearrangement
por: Kim, Tae Hee, et al.
Publicado: (2016) -
Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib
por: Kim, Dae Sik, et al.
Publicado: (2018) -
Pruritus as a Presenting Symptom of FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia
por: Abu-Tineh, Mohammad, et al.
Publicado: (2021) -
Chronic eosinophilic leukemia with FIP1L1-PDGFRA transcripts after occupational and therapeutic exposure to radiation
por: Balatzenko, Gueorgui, et al.
Publicado: (2011) -
Identification of JAK2 as a Mediator of FIP1L1-PDGFRA-Induced Eosinophil Growth and Function in CEL
por: Li, Bin, et al.
Publicado: (2012)